GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Technologies Inc (NAS:MGRM) » Definitions » Intrinsic Value: Projected FCF

Monogram Technologies (Monogram Technologies) Intrinsic Value: Projected FCF : $0.00 (As of May. 23, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Monogram Technologies Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-23), Monogram Technologies's Intrinsic Value: Projected FCF is $0.00. The stock price of Monogram Technologies is $1.98. Therefore, Monogram Technologies's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Monogram Technologies's Intrinsic Value: Projected FCF or its related term are showing as below:

MGRM's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.755
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Monogram Technologies Intrinsic Value: Projected FCF Historical Data

The historical data trend for Monogram Technologies's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Technologies Intrinsic Value: Projected FCF Chart

Monogram Technologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Monogram Technologies Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Monogram Technologies's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Monogram Technologies's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monogram Technologies's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Technologies's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Monogram Technologies's Price-to-Projected-FCF falls into.



Monogram Technologies Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Monogram Technologies  (NAS:MGRM) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Monogram Technologies's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.98/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monogram Technologies Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Monogram Technologies's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Monogram Technologies (Monogram Technologies) Business Description

Traded in Other Exchanges
Address
3913 Todd Lane, Suite 307, Austin, TX, USA, 78744
Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Executives
Paul H Riss director
Noel Knape officer: Chief Financial Officer 3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson director, 10 percent owner, officer: Chief Executive Officer 3913 TODD LANE, AUSTIN TX 78744
Noel Goddard director 3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei officer: Chief Technology Officer 3913 TODD LANE, AUSTIN TX 78744
Douglas Unis director 3913 TODD LANE, AUSTIN TX 78744